Cellution Biologics to Acquire SimpliDerm Dermal Matrix Business
Cellution Biologics signed a deal to buy Elutia's SimpliDerm product line, entering the U.S. breast reconstruction market and broadening its allograft offerings.
Cellution Biologics Inc. has signed a definitive agreement to acquire the SimpliDerm® Human Hydrated Acellular Dermal Matrix business from Elutia Inc., the company announced, marking a strategic push into the U.S. breast reconstruction market and a meaningful expansion of its existing allograft portfolio.
SimpliDerm is an acellular dermal matrix — a processed human tissue product commonly used in reconstructive and plastic surgery procedures. By acquiring this line from Elutia, Cellution Biologics positions itself to compete more directly in a surgical segment where demand for high-quality allograft materials has grown steadily alongside rising breast reconstruction rates in the United States.
Read more Cribl Acquires CardinalOps to Boost AI Security Operations →
The move signals Cellution Biologics' intent to scale its tissue-based product offerings beyond its current lineup. Acellular dermal matrices have become a cornerstone of implant-based breast reconstruction, giving surgeons a biological scaffold that supports tissue integration and reduces complications — making the SimpliDerm acquisition a commercially logical fit for a company already operating in the allograft space.
For Elutia Inc., the divestiture of the SimpliDerm business represents a portfolio rationalization, allowing the seller to focus resources on its remaining product lines. Terms of the transaction were not detailed in the announcement, and the deal remains subject to customary closing conditions.
The acquisition underscores a broader consolidation trend in the regenerative medicine and surgical biologics sector, where smaller specialists are increasingly consolidating tissue-based assets to achieve scale and distribution leverage. Continue reading at GlobalNewswire.
